To evaluate the quality, clinical coherence, consistency and results of randomised controlled trials (RCTs) of nonsurgical treatments for hepatocellular carcinoma.
from the study before its termination; methods used to handle drop-outs and withdrawals in the analysis; evidence of an a priori estimate of sample size.
Completeness of reporting: information on patient characteristics; description of therapeutic regimen; timing of events; reporting of side-effects.
Details of the criteria used are given in an appendix to the paper.
The authors do not state how the papers were assessed for quality, or how many of the authors performed the quality assessment.
Data extraction
The authors do not state how the data were extracted for the review, or how many of the authors performed the data extraction.
Methods of synthesis
How were the studies combined?
The odds ratios (ORs) with 95% confidence intervals (CIs) of 1-year survival rate in treated patients, compared with controls in each trial (in every arm if there were multiple comparisons), were computed using the Mantel-Haenszel method, as described by Peto (see Other Publications of Related Interest). Pooled ORs were computed when there was a similarity between the therapeutic regimens across the trials within each set (chemotherapy, hormonotherapy, embolisation, immunotherapy or other). Pooled ORs are presented for hormonotherapy, embolisation and immunotherapy. Trials in the embolisation set are divided into 3 subsets, where embolisation was:
1. assessed as palliative treatment in unresectable patients; 2. combined with chemotherapy; and 3. assessed as adjuvant therapy in resectable patients.
How were differences between studies investigated?
Inter-trial heterogeneity in treatment effect was evaluated using both a chi-squared test and a visual display (l'Abbe plot). A sensitivity analysis was performed when appropriate.
Results of the review
A total of 37 RCTs (total n=2,824) were included: were reported in some cases. Hormonotherapy (7 trials): pooled OR of 1-year survival was 2.2 (95% CI: 1.4, 3.5; test for heterogeneity, P=0.5); 2-year pooled OR was 1.5 (95% CI: 0.8, 2.7). For 5 trials comparing tamoxifen with non-active treatment: the pooled ORs for survival at 1 and 2 years were 2.0 (95% CI: 1.1, 3.6; test for heterogeneity, P=0.3) and 1.2 (95% CI: 0.6, 2.0), respectively. Side-effects were rare and self-limiting.
Embolisation group 1 (palliative treatment in unresectable patients, 5 trials): 1-year survival pooled OR was 2.0 (95% CI: 1.2, 3.3; test for heterogeneity, P=0.27), although there were differences in the design of the trials, patients' characteristics and treatment regimes. In a subset of 3 trials comparing non-active treatment or intravenous 5-FU, 1and 2-year survival pooled ORs were 2.0 (95% CI: 1.1, 3.6) and 2.3 (95% CI: 1.2, 4.6), respectively.
Embolisation group 2 (with chemotherapeutic agents, 5 trials): for the 2 trials comparing embolisation with and without added chemotherapeutic agents, the results were conflicting. The pooled OR for 1-year survival was 1.2 (95% CI: 0.7, 1.9). For 3 trials comparing several drugs added to embolisation, the 1-year survival pooled OR was 1.0 (95% CI: 0.6, 1.7).
Embolisation group 3 (adjuvant therapy in resectable patients, 3 trials): for 2 trials in which survival could be evaluated, the 1-year survival pooled OR was 0.4 (95% CI: 0.2, 1.0; test for heterogeneity, P=0.1).
In all embolisation trials, side-effects, where discussed, were frequent: 'post-embolisation syndrome' affected 50 to 60% of those treated, and in one study 30 out of 50 patients developed liver failure. Other side-effects reported were acute cholecystitis, gastrointestinal bleeding and peptic ulcer. Immunotherapy (5 trials): in 3 trials comparing interferon-alpha or -beta with chemotherapeutic agents or no treatment, the 1-year survival pooled OR was 2.2 (95% CI: 0.94, 5.2), and the 2-year survival pooled OR was 3.4 (95% CI: 1.1, 10.5). Side-effects included flu-like syndrome in 100% of those treated and 'other' in 55 out of 88 patients. In one study, 16 out of 31 treated patients had severe, life-threatening or lethal toxicities.
Other (3 trials): in a 5-arm RCT, 1-year survival was low or nil in each arm. In one study (antiferritin with doxorubicin and 5-FU versus doxorubicin with 5-FU), a crossover design and unsatisfactory reporting meant the results could not be tabulated. In another study, intra-arterial (iodine-131)-iodised oil was used in patients with portal vein thrombosis with 'apparent good results'.
Authors' conclusions
Most trials had serious methodological and clinical drawbacks. There is no evidence for the efficacy of chemotherapy, either systemic or in addition to embolisation. Treatments with tamoxifen, interferon immunotherapy and embolisation appeared to be marginally effective, and should be further investigated by better, more carefully designed trials.
CRD commentary
On the whole this is a good review with lots of details given about studies included and appropriate analysis. The search strategy could have been more comprehensive: databases other than MEDLINE were not searched and the search was restricted to English language papers. The studies included were all RCTs, which were then graded for quality according to criteria given in the paper, although the grade awarded to each study is not reported or incorporated into the analysis. The results of this 'mini-review' on study design quality are presented in a separate table and discussed separately. An effort was made to avoid double-reporting of trial data by discarding obvious duplicate publications of the same trial. Calculation of the OR for survival at one year for every trial meant that outcomes could be readily compared between groups, but it is questionable whether calculation of this data from plots given in the study papers will be accurate. Heterogeneity analysis was performed within each group and the visual display of the results was explained well. Data were pooled appropriately using a well-explained rationale. Where statistical pooling of data was inappropriate a narrative synthesis was provided instead. Presentation of the results can be difficult to follow due to the amount of detail given. The authors' conclusions are suitably cautious, given the poor quality of the RCTs available in this subject area. 
Implications of the review for practice and research
The implications of this review are that further research, in the form of well-designed and conducted RCTs, should be carried out into the effectiveness of tamoxifen, interferon immunotherapy and embolisation (the three interventions that were not proved ineffective in the review) in the treatment of hepatocellular carcinoma.
